Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Hiroshi Umehara

Preclinical and Phase I Clinical Studies of KW-2450, a Dual IGF-1R/IR Tyrosine Kinase Inhibitor, in Combination With Lapatinib and Letrozole

Therapeutic Advances in Medical Oncology

Oncology

2018

English

Tributylhexadecylphosphonium Bromide, a Novel Nuclear Factor of Activated T Cells Signaling Inhibitor, Blocks Interleukin-2 Induction Associated With Inhibition of P70 Ribosomal Protein S6 Kinase Phosphorylation

Biological and Pharmaceutical Bulletin

Medicine

Pharmacology

Pharmaceutical Science

2012

English

Related publications

Preclinical and First-In-Human Phase I Studies of KW-2450, an Oral Tyrosine Kinase Inhibitor With Insulin-Like Growth Factor Receptor-1/Insulin Receptor Selectivity

English

Discovery of Novel Dual Inhibitors of Receptor Tyrosine Kinases EGFR and IGF-1R

Journal of Enzyme Inhibition and Medicinal Chemistry

English

A Phase I Clinical Trial of FOLFIRI in Combination With the Pan-Cyclin-Dependent Kinase (CDK) Inhibitor Flavopiridol

Cancer Chemotherapy and Pharmacology

English

A Phase I Trial of Combination Trastuzumab, Lapatinib, and Bevacizumab in Patients With Advanced Cancer

Investigational New Drugs

Oncology

Pharmacology

2014

English

A Phase I Study of E7080, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Tumours

British Journal of Cancer

Cancer Research

Oncology

2012

English

Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer

Molecular Cancer Therapeutics

Cancer Research

Oncology

2010

English

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

Clinical Cancer Research

Cancer Research

Oncology

2008

English

Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

Journal of Clinical Pharmacology

Pharmacology

2018

English

ASP9853, an Inhibitor of Inducible Nitric Oxide Synthase Dimerization, in Combination With Docetaxel: Preclinical Investigation and a Phase I Study in Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Hiroshi Umehara

Preclinical and Phase I Clinical Studies of KW-2450, a Dual IGF-1R/IR Tyrosine Kinase Inhibitor, in Combination With Lapatinib and Letrozole

Tributylhexadecylphosphonium Bromide, a Novel Nuclear Factor of Activated T Cells Signaling Inhibitor, Blocks Interleukin-2 Induction Associated With Inhibition of P70 Ribosomal Protein S6 Kinase Phosphorylation

Related publications

Preclinical and First-In-Human Phase I Studies of KW-2450, an Oral Tyrosine Kinase Inhibitor With Insulin-Like Growth Factor Receptor-1/Insulin Receptor Selectivity

Discovery of Novel Dual Inhibitors of Receptor Tyrosine Kinases EGFR and IGF-1R

A Phase I Clinical Trial of FOLFIRI in Combination With the Pan-Cyclin-Dependent Kinase (CDK) Inhibitor Flavopiridol

A Phase I Trial of Combination Trastuzumab, Lapatinib, and Bevacizumab in Patients With Advanced Cancer

A Phase I Study of E7080, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Tumours

Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

ASP9853, an Inhibitor of Inducible Nitric Oxide Synthase Dimerization, in Combination With Docetaxel: Preclinical Investigation and a Phase I Study in Advanced Solid Tumors